Payment overview · 2025
General Payments
$404.58
20 reported records · 10 companies
Healthcare provider profile · identity verified
Jason Charles Saylor, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · TAMPA, FL · NPI 1407086846
Verified facts
What the public records show
CMS Open Payments records show Jason Charles Saylor, D.O. received $404.58 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Nurtec Odt, Otezla, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.28 | 24.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.34 | 14.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.18 | 10.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.55 | 10.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.93 | 9.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.98 | 7.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.82 | 7.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.61 | 7.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.16 | 5.2% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $15.73 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $404.58 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.28 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.13 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.18 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.41 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 84 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 120 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
113 | 31 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
84 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
120 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
286 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1244 | 363 |
| Levothyroxine Sodium | Levothyroxine Sodium | 906 | 241 |
| Lisinopril | Lisinopril | 875 | 249 |
| Amlodipine Besylate | Amlodipine Besylate | 863 | 251 |
| Alprazolam | Alprazolam | 740 | 145 |
| Losartan Potassium | Losartan Potassium | 719 | 201 |
| Pantoprazole Sodium | Pantoprazole Sodium | 590 | 180 |
| Tramadol Hcl | Tramadol Hcl | 587 | 130 |
| Omeprazole | Omeprazole | 575 | 177 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 564 | 167 |
| Metoprolol Succinate | Metoprolol Succinate | 513 | 150 |
| Tamsulosin Hcl | Tamsulosin Hcl | 491 | 135 |
| Metformin Hcl | Metformin Hcl | 487 | 143 |
| Simvastatin | Simvastatin | 487 | 133 |
| Hydrochlorothiazide | Hydrochlorothiazide | 446 | 124 |
| Gabapentin | Gabapentin | 432 | 138 |
| Metoprolol Tartrate | Metoprolol Tartrate | 400 | 110 |
| Lorazepam | Lorazepam | 382 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 336 | 71 |
| Furosemide | Furosemide | 329 | 109 |
| Carvedilol | Carvedilol | 313 | 92 |
| Montelukast Sodium | Montelukast Sodium | 311 | 92 |
| Clopidogrel | Clopidogrel Bisulfate | 292 | 86 |
| Temazepam | Temazepam | 289 | 50 |
| Eliquis | Apixaban | 286 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 281 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 277 | 80 |
| Valsartan | Valsartan | 246 | 71 |
| Clonazepam | Clonazepam | 234 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 233 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 215 | 51 |
| Famotidine | Famotidine | 203 | 60 |
| Glipizide Er | Glipizide | 199 | 57 |
| Potassium Chloride | Potassium Chloride | 191 | 63 |
| Ezetimibe | Ezetimibe | 189 | 59 |
| Allopurinol | Allopurinol | 187 | 50 |
| Trazodone Hcl | Trazodone Hcl | 183 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 179 | 61 |
| Meloxicam | Meloxicam | 179 | 56 |
| Sertraline Hcl | Sertraline Hcl | 167 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 45 |
| Glimepiride | Glimepiride | 162 | 42 |
| Metformin Hcl Er | Metformin Hcl | 158 | 46 |
| Atenolol | Atenolol | 155 | 45 |
| Fenofibrate | Fenofibrate | 145 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 145 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 52 |
| Ozempic | Semaglutide | 143 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 27 |
| Warfarin Sodium | Warfarin Sodium | 132 | 31 |
| Lovastatin | Lovastatin | 127 | 32 |
| Glipizide | Glipizide | 125 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 99 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 29 |
| Mounjaro | Tirzepatide | 120 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 32 |
| Synthroid | Levothyroxine Sodium | 113 | 31 |
| Jardiance | Empagliflozin | 112 | 28 |
| Spironolactone | Spironolactone | 112 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 111 | 91 |
| Xarelto | Rivaroxaban | 110 | 23 |
| Pregabalin | Pregabalin | 109 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 108 | 30 |
| Bupropion Xl | Bupropion Hcl | 105 | 31 |
| Diazepam | Diazepam | 104 | 32 |
| Finasteride | Finasteride | 103 | 29 |
| Donepezil Hcl | Donepezil Hcl | 99 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 27 |
| Alendronate Sodium | Alendronate Sodium | 97 | 30 |
| Prednisone | Prednisone | 95 | 48 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 92 | 77 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 33 |
| Farxiga | Dapagliflozin Propanediol | 84 | 20 |
| Clonidine Hcl | Clonidine Hcl | 82 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 78 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 55 |
| Dicyclomine Hcl | Dicyclomine Hcl | 70 | 21 |
| Nifedipine Er | Nifedipine | 70 | 23 |
| Celecoxib | Celecoxib | 69 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 20 |
| Estradiol | Estradiol | 68 | 23 |
| Methylprednisolone | Methylprednisolone | 68 | 55 |
| Tresiba Flextouch U-100 | Insulin Degludec | 68 | 13 |
| Januvia | Sitagliptin Phosphate | 67 | 13 |
| Chlorthalidone | Chlorthalidone | 65 | 20 |
| Rybelsus | Semaglutide | 61 | 13 |
| Primidone | Primidone | 57 | 14 |
| Enalapril Maleate | Enalapril Maleate | 56 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 18 |
| Bumetanide | Bumetanide | 53 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 13 |
| Baclofen | Baclofen | 52 | 15 |
| Valacyclovir | Valacyclovir Hcl | 52 | 18 |
| Benazepril Hcl | Benazepril Hcl | 51 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Memantine Hcl | Memantine Hcl | 49 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 12 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 43 | 30 |
| Azithromycin | Azithromycin | 42 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 13 |
| Topiramate | Topiramate | 41 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 39 | 39 |
| Meclizine Hcl | Meclizine Hcl | 39 | 19 |
| Sotalol | Sotalol Hcl | 39 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 12 |
| Propranolol Hcl | Propranolol Hcl | 38 | 11 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 14 |
| Acyclovir | Acyclovir | 36 | 11 |
| Nystatin | Nystatin | 36 | 18 |
| Buspirone Hcl | Buspirone Hcl | 35 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Jantoven | Warfarin Sodium | 34 | 17 |
| Ketoconazole | Ketoconazole | 34 | 16 |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 27 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Colchicine | Colchicine | 25 | 11 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 18 |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Indapamide | Indapamide | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Nitroglycerin | Nitroglycerin | 19 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Cymbalta | Duloxetine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $404.58 · 20 records | ABBVIE INC. | Cologuard Collection Kit, FARXIGA, INJECTAFER, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error